Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 404 publications
From Mechanisms to Clinical Practice: Introduction to an AJRCCM Special Section on Interstitial Lung Disease.
Journal: American journal of respiratory and critical care medicine
Published: August 07, 2026
The Gut Speaks to the Lung: Fecal Microbiota and Survival in Idiopathic Pulmonary Fibrosis.
Journal: American journal of respiratory and critical care medicine
Published: July 02, 2026
Gradually, then suddenly: Deconvoluting the natural history of idiopathic pulmonary fibrosis.
Journal: American journal of respiratory and critical care medicine
Published: June 17, 2026
Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPF.
Journal: American journal of respiratory and critical care medicine
Published: April 21, 2026
Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF.
Journal: American journal of respiratory and critical care medicine
Published: April 21, 2026
Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.
Journal: American journal of respiratory and critical care medicine
Published: March 02, 2026
Contribution of dominant and recessive model effects to the genetic architecture of Idiopathic Pulmonary Fibrosis.
Journal: medRxiv : the preprint server for health sciences
Published: February 27, 2026
Effect of nerandomilast on survival in patients with pulmonary fibrosis.
Journal: The European respiratory journal
Published: February 13, 2026
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.
Journal: Research square
Published: February 12, 2026
Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
Journal: Annals of the rheumatic diseases
Published: January 29, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.
Journal: Annals of the rheumatic diseases
Published: December 23, 2025
Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial.
Journal: American journal of respiratory and critical care medicine
Published: December 12, 2025
Last Updated: 09/26/2026